SoftBank slides 12% as OpenAI delays push past 2027, handing the IPO lead to Anthropic

SoftBank Group shares were trading more than 12% lower on the Tokyo morning of 26 June 2026 after a wave of reports that OpenAI's long-awaited public listing has been pushed back into 2027, deferring what would have been one of the most consequential IPOs of the decade. The move marks the sharpest single-session decline in SoftBank's equity in months, and it lands directly on the holding company's most concentrated bet: the roughly $30 billion it has ploughed into OpenAI across successive funding rounds, plus the multi-year commitment to underwrite the Stargate data-centre build-out announced alongside the US administration earlier in the cycle.

The thesis is straightforward. The market had been pricing the OpenAI listing as a near-term liquidity event — a 2026 print that would let SoftBank mark its position to a public quote and begin the slow grind of monetising a balance sheet stretched thin by share buy-backs and chip-related capex. A 2027 listing does not destroy that value, but it does deny SoftBank the one thing it most needs from OpenAI right now: a tape. Without that tape, the holding-company discount that has plagued SoftBank for years widens again, and Masayoshi Son's ability to fund the next leg of AI capex from equity issuance, rather than from additional debt, narrows correspondingly.

What the wires actually said

CryptoBriefing's morning brief on 26 June 2026 reported that OpenAI is now weighing a 2027 listing, framed explicitly against the expectation that Anthropic will debut first. The same wire picked up the equity reaction within hours: SoftBank down 12% on the Tokyo open, attributed by the outlet to "OpenAI IPO delay concerns" rather than to a fundamental re-rating of the underlying AI business. Nikkei Asia's Asia-morning bulletin carried a near-identical line — "Shares in SoftBank Group slipped over 12% on Friday morning as disappointed investors engaged in profit-taking after a report that OpenAI…" — confirming that the move was Tokyo-led and that the catalyst was the timing slip, not a downgrade in OpenAI's underlying valuation.

Two corroborating signals hardened the read. Polymarket's open contract on which lab would list first priced at a 77% implied probability that Anthropic would go public before OpenAI, up sharply on the session. And a separate note circulating on the same morning — flagged by CryptoBriefing — argued that enterprise buyers are pulling back from raw compute "tokenmaxxing" and pivoting toward efficiency, a shift that, if sustained, compresses the revenue trajectory both OpenAI and Anthropic had been projecting through 2026.

The counter-narrative

There are two ways to read the slide that are kinder to the SoftBank thesis. The first is that 2027 is not "delay" in any operational sense — OpenAI continues to ship, continues to raise private capital at flat or rising marks, and continues to anchor the largest compute build-out in the private market. A 12% move on a rephased listing calendar is, on that view, an overreaction by a Tokyo retail and foreign-flow audience that had loaded up on the IPO-print narrative in the first place. The second is that Anthropic's lead in the queue is itself a SoftBank-positive: if Anthropic trades well, the comparable-set valuation for OpenAI rises with it, and SoftBank's eventual mark improves even if it waits a year longer for it.

Neither reading survives contact with the structure of SoftBank's balance sheet. The company has used OpenAI exposure as the de facto justification for an aggressive buy-back programme funded largely by margin loans against its own equity. A longer wait for liquidity raises the mark-to-market risk on those hedges and tightens the constraints on Son's next move. A 12% drop in the parent equity also mechanically raises the cost of every dollar of future AI capex funded through asset sales or pledges of the OpenAI stake itself. The Polymarket print, in other words, is not the news — it is the price discovery on a funding-stress story that had been hiding inside the IPO-narrative trade.

What we verified, and what we could not

What we verified from the source items: that on 26 June 2026, SoftBank Group shares fell more than 12% on the Tokyo session; that the move was attributed by CryptoBriefing and Nikkei Asia specifically to a reported delay to OpenAI's IPO into 2027; that Polymarket's contract on Anthropic-vs-OpenAI listing order priced at a 77% implied probability of Anthropic first; and that CryptoBriefing flagged a separate market claim about enterprise customers moving away from "tokenmaxxing" toward efficiency.

What we could not verify from the source items: the underlying OpenAI valuation figure that 2027 pricing would imply; whether the IPO delay has been formally announced by OpenAI or remains a report-stage claim; whether SoftBank's margin debt against its own equity has been extended or rolled in the wake of the move; whether Anthropic's S-1, if filed, would name OpenAI as a comparable; and the identity of the trader or fund that drove the initial Tokyo leg of the drop. The sources do not specify these.

The structural frame

Two patterns are worth naming. First, the AI capex cycle is increasingly being priced not by what frontier labs can sell, but by when those labs can convert private marks into public ones. The Polymarket contract, the SoftBank slide, and the CryptoBriefing/Nikkei Asia IPO-timing dispatches are all expressions of the same underlying question: how long can the leading labs remain private before the holding-company vehicles that own them run out of road? Second, the shift from "tokenmaxxing" — buying raw inference at any cost to ship a product — toward efficiency is a margin story masquerading as a growth story. If enterprise buyers are squeezing unit economics at the same moment that the labs' own listing windows slide, the multiple compression is going to land harder on the second-tier private marks than on the leaders, because the leaders still have the IPO optionality. That asymmetry is what the SoftBank slide is, mechanically, pricing.

The stakes

For OpenAI, a 2027 listing pushes the company through another full year of capex without a public-market backstop, against an Anthropic narrative that will be able to point to its own S-1 and its own day-one tape. For Anthropic, the same window is a once-per-cycle marketing asset — the company that priced the market for the category. For SoftBank, the calculus is binary: either the IPO prints in 2027 at a flat-or-rising mark and the buy-back-and-capex programme survives, or the mark drifts and the holding-company discount reasserts itself as the dominant factor on the equity. For the broader public market, the read-through is that AI exposure, which has spent two years trading as a growth story, is now being repriced as a duration story — and duration, when it extends, is rarely rewarded.

The next data points to watch are simple: any OpenAI filing or formal statement on listing timing; the next Polymarket print on the Anthropic-first contract; and the Tokyo open on 27 June 2026, which will tell the trade whether Friday's 12% was a flush or the start of a new regime.

Monexus framed this as a balance-sheet event at a holding company, not as an AI-fundamentals story. The wires led on the IPO-timing slip; we led on what that slip costs the vehicle that owns the position.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://t.me/CryptoBriefing
• https://t.me/CryptoBriefing
• https://x.com/polymarket/status/2069859022790959104
• https://x.com/polymarket/status/2069859022790959104
• https://t.me/NikkeiAsia
• https://t.me/nikkeiasia